Keith Kennedy - 05 Nov 2026 Form 4 Insider Report for CareDx, Inc. (CDNA)

Reporting relationship: CFO & COO
Issuer ticker: CDNA
Reported as of: 05 Nov 2026
Net transaction value: -$4,821,711
SEC form: 4
Accepted by SEC: 09 Nov 2026, 18:26:23 UTC
Prior SEC filing: 05 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Adam Novack, Attorney-in-Fact

Filing notes and source

Key filing fact

Keith Kennedy filed Form 4 for CareDx, Inc. (CDNA) on 09 Nov 2026.

Key facts

This page summarizes Keith Kennedy's Form 4 filing for CareDx, Inc. (CDNA).
10 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 09 Nov 2026, 18:26.

Change

Previous filing in this sequence was filed on 05 Oct 2026.
Current net transaction value: -$4,821,711.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001543503 Primary reporting owner

Kennedy Keith

Relationship: CFO & COO
Address: C/O CAREDX, INC., 8000 MARINA BOULEVARD, 4TH FLOOR, BRISBANE
Signature: /s/ Jeffrey Adam Novack, Attorney-in-Fact
Signature date: 09 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CDNA transaction

Common Stock

Options Exercise

Transaction value
Shares: +52,422
Change %: +25%
Price: $29.43^*
Shares after: 261,108
Date: 05 Nov 2026
Ownership: Direct

CDNA transaction

Common Stock

Sale

Transaction value: -$2,162,954
Shares: -28,256
Change %: -11%
Price: $76.55
Shares after: 232,852
Date: 05 Nov 2026
Ownership: Direct
Footnotes: F1, F2

CDNA transaction

Common Stock

Sale

Transaction value: -$958,440
Shares: -12,380
Change %: -5.3%
Price: $77.42
Shares after: 220,472
Date: 05 Nov 2026
Ownership: Direct
Footnotes: F1, F3

CDNA transaction

Common Stock

Sale

Transaction value: -$542,018
Shares: -6,897
Change %: -3.1%
Price: $78.59
Shares after: 213,575
Date: 05 Nov 2026
Ownership: Direct
Footnotes: F1, F4

CDNA transaction

Common Stock

Sale

Transaction value: -$589,383
Shares: -7,415
Change %: -3.5%
Price: $79.49
Shares after: 206,160
Date: 05 Nov 2026
Ownership: Direct
Footnotes: F1, F5

CDNA transaction

Common Stock

Sale

Transaction value: -$273,527
Shares: -3,403
Change %: -1.7%
Price: $80.38
Shares after: 202,757
Date: 05 Nov 2026
Ownership: Direct
Footnotes: F1, F6

CDNA transaction

Common Stock

Sale

Transaction value: -$220,605
Shares: -2,710
Change %: -1.3%
Price: $81.40
Shares after: 200,047
Date: 05 Nov 2026
Ownership: Direct
Footnotes: F1, F7

CDNA transaction

Common Stock

Sale

Transaction value: -$24,623
Shares: -300
Change %: -0.15%
Price: $82.08
Shares after: 199,747
Date: 05 Nov 2026
Ownership: Direct
Footnotes: F1, F8

CDNA transaction

Common Stock

Sale

Transaction value: -$50,160
Shares: -600
Change %: -0.3%
Price: $83.60
Shares after: 199,147
Date: 05 Nov 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CDNA transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -52,422
Change %: -52%
Price: $0.000000^*
Shares after: 48,229
Date: 05 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 52,422
Exercise price: $29.43
Footnotes: F9

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 9 footnotes

Footnote F1

The transaction reported in this row was effected pursuant to a Rule 10b5-1 trading plan, adopted by the Reporting Person on August 6, 2026.

Footnote F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.00 to $76.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.00 to $77.99 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.00 to $78.97 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.00 to $79.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F6

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.95 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F7

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.94 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F8

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.07 to $82.08 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F9

1/4th of the shares subject to this option shall vest on September 12, 2025 and 1/48th of the shares subject to the option shall vest monthly thereafter through September 30, 2028.